The generic drug developed by Zhejiang Jingxin Pharmaceutical to treat Alzheimer’s disease has obtained the official approval document on drug registration issued by the China Food and Drug Administration. It is the first generic drug of its kind with an approval document number in China.
The Xinchang-based company received the five-year approval for 1.5 milligram and 3 mg rivastigmine hydrogen tartrate capsules, it said in a statement yesterday.
The rivastigmine hydrogen tartrate is a first-line drug developed by Swiss Novartis International to treat mild to moderate level of Alzheimer’s disease. The drug was first released years ago. Jingxin Pharma is the first Chinese drug maker that has obtained the official approval document for this kind of medicine, the statement added.
Alzheimer’s disease is a chronic neurodegenerative disease that progresses over time. It is the cause of nearly two-thirds of cases of dementia.
Compared with similar drugs, the rivastigmine hydrogen tartrate has a higher therapeutic index, and reduces the use of antipsychotic drugs and auxiliary tranquillizers during the treatment. Furthermore, patients are well tolerant to the drug and can achieve noticeable therapeutic results, it said.
It is also the first drug developed by the company to treat Alzheimer’s disease, and will expand the scope of the firm’s neuropsychiatric drugs if approved, making a positive impact on its business, the statement added.
Source: yicaiglobal.com
